Orally Available Small Molecule Regulates TXNIP Expression and Glucagon Action for the Treatment of Diabetes
Preprint
- 9 January 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
In the progression of diabetes, sustained glucagon secretion facilitates glucose production. Despite its significance, no treatments currently target this vital parameter. We employed the promoter sequence of thioredoxin-interacting protein (TXNIP) as a screening target, evaluated our in-house chemical library, and subsequently undertook high-throughput screening and optimization via various medicinal chemistry techniques. Our efforts led to the identification of SKL-1223, an orally administered, non-toxic small molecule capable of effectively regulating blood glucose levels in both streptozotocin-induced and obesity-induced (db/db) diabetic mice. Furthermore, our study elucidated the hypoglycemic effect of glucagon and its role in reducing hepatic glucose output. On a mechanistic level, SKL-1223 interacts with the E-box region of the TXNIP promoter, consequently suppressing TXNIP transcription and associated signaling pathways. Thus, our study introduces a novel compound, offering a fresh therapeutic avenue for diabetes beyond existing regimens.Keywords
All Related Versions
This publication has 49 references indexed in Scilit:
- SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world studyDiabetologia, 2023
- Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonistCell Metabolism, 2022
- Streptozotocin‐Induced Diabetic Models in Mice and RatsCurrent Protocols, 2021
- Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon ActionCell Metabolism, 2020
- Metabolite therapy guided by liquid biopsy proteomics delays retinal neurodegenerationEBioMedicine, 2020
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risksThe Lancet Diabetes & Endocrinology, 2019
- Characterization of the db/db Mouse Model of Type 2 Diabetes2018
- Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 DiabetesCell, 2017
- db/+ Mice as an Alternate Model in Antidiabetic Drug Discovery ResearchArchives of Medical Research, 2009
- THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUSThe Lancet, 1975